BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28377179)

  • 1. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
    Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
    Sokolenko AP; Bizin IV; Preobrazhenskaya EV; Gorodnova TV; Ivantsov AO; Iyevleva AG; Savonevich EL; Kotiv KB; Kuligina ES; Imyanitov EN
    Int J Cancer; 2020 Apr; 146(7):1879-1888. PubMed ID: 31693165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.
    Sokolenko A; Preobrazhenskaya E; Marchetti C; Piermattei A; Zagrebin F; Kuligina E; Gorodnova T; Pavone M; Ivantsov A; Bizin I; Scambia G; Berlev I; Fagotti A; Imyanitov E
    Pathobiology; 2024; 91(2):108-113. PubMed ID: 37579727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Gorodnova TV; Sokolenko AP; Ivantsov AO; Iyevleva AG; Suspitsin EN; Aleksakhina SN; Yanus GA; Togo AV; Maximov SY; Imyanitov EN
    Cancer Lett; 2015 Dec; 369(2):363-7. PubMed ID: 26342406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
    Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor
    Afghahi A; Timms KM; Vinayak S; Jensen KC; Kurian AW; Carlson RW; Chang PJ; Schackmann E; Hartman AR; Ford JM; Telli ML
    Clin Cancer Res; 2017 Jul; 23(13):3365-3370. PubMed ID: 28087643
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
    Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
    Gorodnova TV; Maksimov SIa; Guseĭnov KD; Imianitov EN
    Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
    Gorodnova TV; Kotiv KB; Ivantsov AO; Mikheyeva ON; Mikhailiuk GI; Lisyanskaya AS; Mikaya NA; Guseynov KD; Bondarev NE; Matveyeva NS; Nekrasova EA; Sidoruk AA; Roman LD; Manikhas GM; Belyaev AM; Sokolenko AP; Berlev IV; Imyanitov EN
    Int J Gynecol Cancer; 2018 Oct; 28(8):1498-1506. PubMed ID: 30247247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Wang J; Gao H; Liu G; Gu L; Yang C; Zhang F; Liu T
    Hum Pathol; 2018 Dec; 82():239-248. PubMed ID: 30107189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of bevacizumab to neoadjuvant chemotherapy for Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report.
    Liu H; Shi Y; Zhang GN; Song SQ; Hu T
    Eur J Gynaecol Oncol; 2015; 36(3):341-5. PubMed ID: 26189267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
    J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
    Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD
    J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in
    Sokolenko AP; Moiseyenko FV; Iyevleva AG; Ivantsov AO; Dolmatov GD; Shelekhova KV; Gulo EV; Topal AX; Artemieva EV; Abduloeva NH; Rysev NA; Barsova DA; Levchenko NV; Volkov NM; Egorenkov VV; Moiseyenko VM; Imyanitov EN
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.